Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Juvenile Myelomonocytic Leukemia
Conditions
Brief summary
The radio-labeled anti-CD66 monoclonal antibody (with 111In for dosimetry and 90Y for therapy) will be administered in the T11 North room, UCLH, while the reduced intensity conditioning regimen and the allogeneic hematopoietic stem cell transplant will be performed in 2 centers, according to the age of the patient: A) patients aged \< 13 years will be transplanted at the Bone Marrow Transplantation Department, Great Ormond Street Hospital (GOSH), and B) patients aged 13-18 years will be transplanted at the Bone Marrow Transplantation Department, University College London Hospitals (UCLH).
Interventions
OTHERYttrium-90 labelled monoclonal antibody against CD66
Sponsors
Great Ormond Street Hospital for Children NHS Foundation Trust
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Yttrium-90 labelled monoclonal antibody against CD66
Intervention model description
3+3 Dose escalation study, patient will receive 111In-labelled anti-CD66 MoAb (dosimetry) and 90Yttrium-labelled anti-CD66 MoAb (for therapy)
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. An underlying haematological malignancy including: 1. isolated bone marrow relapse of AML after allogeneic haematopoietic stem cell transplantation; 2. isolated bone marrow relapse of ALL after allogeneic haematopoietic stem cell transplantation; 3. bone marrow relapse of JMML after allogeneic haematopoietic stem cell transplantation; 4. refractory AML (5-20% blasts in BM) with/without expression of CD66 on blasts; 5. refractory ALL (5-20% blasts in BM) with/without expression of CD66 on blasts; 6. refractory AML (\> 20% blasts in BM) with expression of CD66 on blasts; 7. refractory ALL (\> 20% blasts in BM) with expression of CD66 on blasts; 2. be ≥ 1 year old and ≤ 18 years old; 3. must not be eligible for therapy of higher curative potential. Where an alternative therapy has been shown to prolong survival in an analogous population, this should be offered to the patient prior to discussing this study; 4. have a Karnofsky Performance Status ≥ 50 or Lansky Performance Status ≥ 30; 5. provide signed, written informed consent from parent or guardian; 6. be able to comply with study procedures and follow-up examinations; 7. have normal cardiac function without specific treatment; 8. have adequate organ function (as indicated by Table 3, chapter 5), within 30 days prior to 111In infusion; 9. patients who have received any other chemotherapy within the previous 2 weeks and must have recovered from acute toxicity of all previous therapy prior to enrolment; 10. be negative for human-anti-murine antibodies (HAMA).
Exclusion criteria
1\) patients with CNS disease; 2) patients with BM cellularity \< 10%; 3) patients with ≥ 20% blasts in BM and no expression of CD66 on blasts; 4) patients who are positive for human-anti-murine antibodies (HAMA); 5) patients with compromised organ function (as indicated by Table 3, chapter 5), within 30 days prior to 111In infusion; 6) patients with extensive chronic GvHD; 7) patients with an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment; 8) patients who are pregnant or lactating; 9) patients with any other severe concurrent disease, which, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| maximum tolerated dose (MTD) | 45 days post transplant | targeted radiotherapy delivered by 90Yttrium-labelled anti-CD66 |
| dose limited toxicity (DLT) | 45 days post transplant | targeted radiotherapy delivered by 90Yttrium-labelled anti-CD66 |
Countries
United Kingdom
Outcome results
None listed